ILLUMINA, INC.ILMNEarnings & Financial Report
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
ILMN Q1 FY2027 Key Financial Metrics
Revenue
$1.1B
Gross Profit
$721.0M
Operating Profit
$209.0M
Net Profit
$134.0M
Gross Margin
66.1%
Operating Margin
19.2%
Net Margin
12.3%
YoY Growth
4.8%
EPS
$0.87
ILLUMINA, INC. Q1 FY2027 Financial Summary
ILLUMINA, INC. reported revenue of $1.1B (up 4.8% YoY) for Q1 FY2027, with a net profit of $134.0M (12.3% margin). Cost of goods sold was $370.0M, operating expenses totaled $512.0M.
Key Financial Metrics
| Total Revenue | $1.1B |
|---|---|
| Net Profit | $134.0M |
| Gross Margin | 66.1% |
| Operating Margin | 19.2% |
| Report Period | Q1 FY2027 |
Revenue Breakdown
ILLUMINA, INC. Q1 FY2027 revenue of $1.1B breaks down across 2 segments, led by Product revenue at $917.0M (84.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product revenue | $917.0M | 84.1% |
| Service and other revenue | $174.0M | 15.9% |
ILLUMINA, INC. Revenue by Segment — Quarterly Trend
ILLUMINA, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Product revenue and Service and other revenue) has evolved quarter over quarter.
| Segment | Q1 FY2027 | Q4 FY2025 | Q4 FY2024 | Q3 FY2024 |
|---|---|---|---|---|
| Product revenue | $917.0M | $990.0M | — | — |
| Service and other revenue | $174.0M | $169.0M | — | — |
ILLUMINA, INC. Annual Revenue by Year
ILLUMINA, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $4.4B).
ILLUMINA, INC. Quarterly Revenue & Net Profit History
ILLUMINA, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2027 | $1.1B | +4.8% | $134.0M | 12.3% |
| Q4 FY2025 | $1.2B | +5.0% | $334.0M | 28.8% |
| Q4 FY2024 | $1.1B | -1.6% | $186.0M | 16.8% |
| Q3 FY2024 | $1.1B | -3.5% | $705.0M | 65.3% |
| Q2 FY2024 | $1.1B | -5.4% | $-2.0B | -178.8% |
| Q1 FY2024 | $1.1B | -1.0% | $-126.0M | -11.7% |
| Q4 FY2023 | $1.1B | +3.5% | $-176.0M | -15.7% |
| Q3 FY2023 | $1.1B | +0.4% | $-754.0M | -67.4% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q4 2025 | Q1 2027 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $1.12B | $1.08B | $1.11B | $1.08B | $1.10B | $1.16B | $1.09B |
| YoY Growth | 0.4% | 3.5% | -1.0% | -5.4% | -3.5% | -1.6% | 5.0% | 4.8% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q4 2025 | Q1 2027 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.12B | $10.11B | $10.04B | $6.08B | $6.01B | $6.30B | $6.64B | $6.56B |
| Liabilities | $4.22B | $4.37B | $4.31B | $4.64B | $3.89B | $3.93B | $3.92B | $3.88B |
| Equity | $5.90B | $5.75B | $5.73B | $1.44B | $2.13B | $2.37B | $2.72B | $2.68B |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q4 2025 | Q1 2027 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $139.0M | $224.0M | $77.0M | $80.0M | $316.0M | $364.0M | $321.0M | $289.0M |